HCP
ACAD icon

Hexagon Capital Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Hexagon Capital Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,137
Closed -$18.9K – 87
2025
Q1 		$18.9K Sell
1,137
-198
-15% -$3.6K ﹤0.01% 779
2024
Q4 		$24.5K Buy
1,335
+4
+0.3% +$65 ﹤0.01% 719
2024
Q3 		$20.5K Buy
1,331
+145
+12% +$2.42K ﹤0.01% 707
2024
Q2 		$19.3K Buy
1,186
+852
+255% +$13.8K ﹤0.01% 698
2024
Q1 		$6.18K Buy
334
+300
+882% +$7.43K ﹤0.01% 960
2023
Q4 		$1.06K Buy
+34
New +$812 ﹤0.01% 1222

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Hexagon Capital Partners's ACAD Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Acadia Pharmaceuticals (ACAD) in Q2 2025, closing a stake of 1,137 shares — an estimated $18.9K sold.

Hexagon Capital Partners first reported a position in ACAD in Q4 2023 and held it in 6 quarters. The position peaked at $24.5K in Q4 2024. 311 funds tracked by Wall St. Rank hold ACAD as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Acadia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 1,137 Acadia Pharmaceuticals shares in Q2 2025, an estimated $18.9K.
  • Hexagon Capital Partners first reported a position in Acadia Pharmaceuticals in Q4 2023 and held it in 6 quarters.
  • Hexagon Capital Partners's Acadia Pharmaceuticals position peaked at $24.5K in Q4 2024.
  • 311 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.